US approves first new Alzheimer’s drug in 20 years
There has been controversy around aducanumab, which targets the cause rather than the symptoms. …
In March 2019, late-stage international trials of aducanumab, involving about 3,000 patients, were halted when analysis showed the drug, given as a monthly infusion, was not better at slowing the deterioration of memory and thinking problems than a dummy drug.
About The Author
